<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131624</url>
  </required_header>
  <id_info>
    <org_study_id>FER-ASAP-2009-01</org_study_id>
    <nct_id>NCT01131624</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women</brief_title>
  <acronym>ASAP</acronym>
  <official_title>An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierrel Research Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at how well Ferric Carboxymaltose, an intravenous iron
      therapy (iron that is infused directly into your body through a vein), compares with ferrous
      sulphate capsules taken by mouth in the treatment of iron deficiency anaemia during
      pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicentre, randomised, 2-arm study to assess the efficacy and safety
      of FCM compared to oral iron in pregnant women with IDA.

      During the screening period (Days -10 to 0 before randomisation), subjects will be selected
      based on eligibility criteria. Subjects who meet all of the inclusion criteria and none of
      the exclusion criteria will undergo baseline assessments at baseline (Day 0) prior to the
      first dose of study medication.

      Subjects will be randomised to receive either intravenous (IV) iron (FCM, 1,000-1,500 mg) or
      oral iron (ferrous sulphate, 100 mg iron twice a day; total dose 200 mg/day).

      The treatment period will begin with the infusion of FCM or the intake of oral iron on Day 0.

      All subjects will return for assessment of efficacy and safety at Weeks 3, 6, 9, 12 and at
      delivery (or whichever comes first).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Hb increase after 3 weeks in FCM compared to oral iron treated subjects (superiority).</measure>
    <time_frame>3 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hb from baseline at Week 6</measure>
    <time_frame>6 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb from baseline at Week 9</measure>
    <time_frame>9 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb from baseline at Week 12</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.
subjects with bw &lt;66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferrous sulphate</intervention_name>
    <description>200 mg iron per day in a convenient dosage schedule.</description>
    <arm_group_label>Oral Iron</arm_group_label>
    <other_name>Oral Iron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <description>1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.</description>
    <arm_group_label>Ferric carboxymaltose</arm_group_label>
    <other_name>Ferric carboxymaltose</other_name>
    <other_name>FCM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women aged ≥18, gestational week ≥20, ≤33 at baseline visit with normal
             antenatal screening test results.

          -  Iron deficiency anaemia defined as Hb concentration ≥8 g/dl and ≤10.4 g/dL and serum
             ferritin ≤20 mcg/L at screening.

          -  Demonstrated the ability to understand the requirements of the study, abide by the
             study restrictions, and agree to return for the required assessments. Patients (or
             their representative) must provide written informed consent for their participation in
             the study.

        Exclusion Criteria:

          -  Blood transfusion, erythropoietin treatment, parenteral iron or oral iron treatment (1
             month prior to screening) or anticipated need for a blood transfusion during the
             study.

          -  Anaemia not caused by iron deficiency (e.g., aplastic, megaloblastic or haemolytic
             anaemia) or related to acute or ongoing, haemoglobinopathies, rheumatic and other
             chronic diseases, autoimmune diseases, malignancies, bone marrow diseases, enzyme
             defects and drug induced anaemia.

          -  Acute or chronic infection, clinically relevant active inflammatory disease
             (C-reactive protein &gt;10 mg/dl or outside reference range), any acute infection at
             screening.

          -  Pre-eclampsia.

          -  Multiple pregnancy.

          -  Evidence on any significant abnormalities on anomaly ultrasound.

          -  Haemochromatosis or other iron storage disorders.

          -  Folate deficiency (S-folate &lt;4.5 nmol/L) at screening.

          -  Vitamin B12 deficiency (S-cobalamin &lt;145 pmol/L) at screening.

          -  Serious medical condition, uncontrolled systemic disease or any other medical
             condition that, in the judgment of the Investigator, prohibits the patient from
             entering or potentially completing the study.

          -  Known chronic renal failure (defined as creatinine clearance &lt;30 mL/min calculated by
             Cockcroft-Gault or modification of diet in renal disease formula).

          -  Severe cardiovascular diseases.

          -  Known human immunodeficiency virus/acquired immunodeficiency syndrome, hepatitis B
             virus or hepatitis C virus infection.

          -  Inability to fully comprehend and/or perform study procedures in the Investigator's
             opinion

          -  History of endocrine disorders

          -  Ongoing significant neurological or psychiatric disorders including psychotic
             disorders or dementia

          -  Recent significant bleeding/surgery (within the 3 months prior to screening).

          -  Chronic/acute hepatic disorder or elevating of liver enzymes (aspartate
             aminotransferase, alanine aminotransferase) over 2 times above the upper normal limit
             at screening.

          -  Participation in any other interventional study since estimated conception and
             throughout study participation.

          -  Known hypersensitivity to FCM or other IV iron preparations.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Breymann</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Northern Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln, Klinikum für Geburtsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Für Frauenheilkunde und Geburtshilfe Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatalzentrum, Klinikum Innenstadt LMU</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kvinnokliniken, Falu lasarett</name>
      <address>
        <city>Falun</city>
        <zip>SE-791</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kvinnokliniken, University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kvinnokliniken, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge, Centrum för fostermedicin KK</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Dept of obstetrics and gynecology Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel, Geburtshilfe und Schwangerschaftsmedizin Frauenklinik</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humboldtstrasse</name>
      <address>
        <city>Bern</city>
        <zip>3013</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG, Département de Gynécologie-Obstétrique</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV, Département de Gynécologie-Obstétrique</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OR Lugano, sede Ospedale Civico, Clinica ginecologia ostetricia</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich, Departement Frauenheilkunde</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cukurova University Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Uni. Ist. Med. Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeynep Kamil Hospital, Arakiyeci Haci Mehmet Mahallesi.</name>
      <address>
        <city>Istanbul</city>
        <zip>34668</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kutfi Kirdar Kartal Research and Education Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Saudi Arabia</country>
  </removed_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

